The Scottish Medicines Consortium has approved osimertinib for adults with unresectable stage III EGFR-mutant NSCLC whose disease has not progressed after platinum-based chemoradiation.

BDTX bets on silevertinib's broad EGFR mutation reach and CNS activity, but with no approved products, upcoming 2026 data and partnerships are pivotal.

The Lung Cancer Research Foundation (LCRF) announces the first recipients of its LCRF Team Science Award on Advancing ...

Several reports have noted that individuals with NSCLC whose tumors are documented to contain a mutation in the EGFR receptor have a substantially greater chance of responding to small-molecule ...

Black Diamond Therapeutics, Inc. BDTX offers a high-leverage oncology setup built around one primary value driver: silevertinib, a brain-penetrant, fourth-generation epidermal growth factor receptor ...

Panelists discuss how EGFR mutation profiling guides targeted first-line NSCLC therapy and shifts care toward precision medicine. Panelists discuss how understanding EGFR mutations has transformed the ...

Afatinib almost doubled progression-free survival versus chemotherapy in advanced lung cancer with uncommon EGFR mutations. The treatment effect was consistent across major uncommon mutations, ...

SAN DIEGO--(BUSINESS WIRE)--Cellworks Group Inc., a leader in Personalized Therapy Decision Support and Precision Drug Development, today announced findings from a study using the Cellworks Platform ...

Detailed price information for Arrivent Biopharma Inc (AVBP-Q) from The Globe and Mail including charting and trades.

Retrospective review of 33,850 molecularly profiled ovarian cancer samples from real-world patients who underwent next-generation sequencing (NGS) of DNA between 2016 and 2025. EGFR-mutated cases were ...